Owkin 与阿斯利康签订三年 K Pro 许可安排
Public reviewed event · Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
Event summary
据 Owkin 官方公告，与阿斯利康达成安排，基于三年 K Pro 许可开发生物医药 AI 智能体。不是已验证的临床效果。
Public evidence and original sources
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro
Owkin official newsroom